Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
| Autor: | Alejandra Ivars, Fernando Aranda, Guido Kroemer, Aitziber Buqué, Laurence Zitvogel, Radek Spisek, Manuel Cánovas, Elena García-Martínez, Ma Angeles Vicente Conesa, Lorenzo Galluzzi, Francisco Ayala de la Peña, Jitka Fucikova, Melody Smith |
|---|---|
| Přispěvatelé: | Université Paris-Sud - Paris 11 (UP11), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris-Sud - Paris 11 ( UP11 ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
lcsh:Immunologic diseases. Allergy Immunology [ SDV.IMM.IMM ] Life Sciences [q-bio]/Immunology/Immunotherapy [SDV.CAN]Life Sciences [q-bio]/Cancer Pembrolizumab Review Recombinant Interleukin lcsh:RC254-282 [ SDV.CAN ] Life Sciences [q-bio]/Cancer 03 medical and health sciences 0302 clinical medicine Immune system Pleiotropism PD-1 Immunology and Allergy Medicine CTLA4 CAR T cells business.industry Cancer GM-CSF [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy medicine.disease Acquired immune system lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immune checkpoint 3. Good health 030104 developmental biology Oncology IL-15 Interleukin 15 030220 oncology & carcinogenesis pembrolizumab business lcsh:RC581-607 |
| Zdroj: | OncoImmunology OncoImmunology, Taylor & Francis, 2018, 7 (6), pp.e1433982. ⟨10.1080/2162402X.2018.1433982⟩ OncoImmunology, Taylor & Francis, 2018, 7 (6), pp.e1433982. 〈10.1080/2162402X.2018.1433982〉 OncoImmunology, Vol 7, Iss 6 (2018) |
| ISSN: | 2162-4011 2162-402X |
| DOI: | 10.1080/2162402X.2018.1433982⟩ |
| Popis: | International audience; Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-α2a and IFN-α2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-α2a and IFN-α2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|